Moderate-Vigorous Physical Activity across Body Mass Index in Females: Moderating Effect of Endocannabinoids and Temperament

Fernando Fernández-Aranda1,2,3,4, Sarah Sauchelli15, Antoni Pastor2,4,5, Marcela L. González6, Rafael de la Torre2,5,7, Roser Granero2,8, Susana Jiménez-Murcia1,2,3, Rosa Baños9, Cristina Botella2,10, Jose M. Fernández-Reali2,11, Jose C. Fernández-García2,12, Gema Frühbeck2,13, Javier Gómez-Ambrosi2,13, Roser Rodríguez2,11, Francisco J. Tinhahones2,12, Jon Arcelus14, Ana B. Fagundo1,2, Zaida Aguera1,2, Jordi Miró7, Felipe F. Casanueva2,15*

1 Department of Psychiatry, University Hospital of Bellvitge-IDIBELL, Barcelona, Spain, 2 CIBER Fisiopatología Obesidad y Nutrición (CIBERobn), Instituto Salud Carlos III, Madrid, Spain, 3 Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain, 4 Department of Pharmacology, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain, 5 Human Pharmacology and Clinical Neurosciences Research Group, Neuroscience Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain, 6 Department of Psychology, Universitat Rovira i Virgili, Tarragona, Spain, 7 Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain, 8 Departament de Psicobiologia i Metodologia, Universitat Autònoma de Barcelona, Barcelona, Spain, 9 Department of Psychological, Personality, Evaluation and Treatment of the University of Valencia, Valencia, Spain, 10 Department of Basic Psychology, Clinic and Psychobiology of the University Jaume I, Castellón, Spain, 11 Department of Diabetes, Endocrinology and Nutrition, Institut d’Investigació Biomèdica de Girona (IdIBGI), Hospital Dr Josep Trueta, Girona, Spain, 12 Department of Diabetes, Endocrinology and Nutrition, Hospital Clínic Universitari Virgen de Victoria, Málaga, Spain, 13 Department of Endocrinology and Nutrition, Clinica Universitària de Navarra, University of Navarra, Pamplona, Spain, 14 Eating Disorders Service, Glenfield University Hospital, Leicester, United Kingdom, 15 Department of Medicine, Endocrinology Division, Santiago de Compostela University, Complejo Hospitalario Universitario, Santiago de Compostela, Spain

Abstract

Background: Endocannabinoids and temperament traits have been linked to both physical activity and body mass index (BMI) however no study has explored how these factors interact in females. The aims of this cross-sectional study were to 1) examine differences among distinct BMI groups on daytime physical activity and time spent in moderate-vigorous physical activity (MVPA), temperament traits and plasma endocannabinoid concentrations; and 2) explore the association and interaction between MVPA, temperament, endocannabinoids and BMI.

Methods: Physical activity was measured with the wrist-worn accelerometer Activwatch AW7, in a sample of 189 female participants (43 morbid obese, 30 obese, and 116 healthy-weight controls). The Temperament and Character Inventory-Revised questionnaire was used to assess personality traits. BMI was calculated by bioelectrical impedance analysis via the TANITA digital scale. Blood analyses were conducted to measure levels of endocannabinoids and endocannabinoid-related compounds. Path-analysis was performed to examine the association between predictive variables and MVPA.

Results: Obese groups showed lower MVPA and dysfunctional temperament traits compared to healthy-weight controls. Plasma concentrations of 2-arachidonoylglycerol (2-AG) were greater in obese groups. Path-analysis identified a direct effect between greater MVPA and low BMI ($b = -0.13, p = .039$) and high MVPA levels were associated with elevated anandamide (AEA) levels ($b = 0.16, p = .049$) and N-arachidonyl ethanamide (OEA) levels ($b = 0.22, p = .004$), as well as high Novelty seeking ($b = 0.18, p < .001$) and low Harm avoidance ($b = -0.16, p < .001$).

Conclusions: Obese individuals showed a distinct temperament profile and circulating endocannabinoids compared to controls. Temperament and endocannabinoids may act as moderators of the low MVPA in obesity.
Introduction

There is a growing prevalence of obesity and overweight worldwide. A fall in energy expenditure is believed to be one of the leading lifestyle changes boosting the notable spread of obesity [1]. Prolonged sedentary behavior has been strongly associated with this extreme weight condition and a consequent increase in the likelihood of cardiovascular diseases, hypertension, type 2 diabetes, and osteoporosis [2]. Differently, regular exercise or structured moderate-vigorous physical activity (MVPA) facilitates weight control [3].

These changes in physical activity (PA) patterns are of particular concern for females. The prevalence of obesity has been estimated to be greater among females than males (11.9% versus 7.7%) across all studied world regions [2]. In addition, females spend less time engaging in MVPA and more in sedentary activities, a gender difference especially seen among younger adults [4]. Given this evidence, and that the decline in PA over time is especially present among females [5], there is an urgent need to understand the mechanisms underlying the inter-individual fluctuations in structured PA and their relationship to body mass index (BMI) in females.

Moderate-Vigorous Physical Activity /BMI and Endocannabinoids

Biological models have been proposed to explain individual differences in MVPA. Studies have identified the role of the endocannabinoid (eCB) system in the engagement and maintenance of structured PA, interacting with the reward neurosystem of exercise [6,7]. It has been suggested that the beneficial effects of PA for cognitive function may be partly related to the eCB system [8]. The eCB system is also known for its modulation of cognitive and emotional behavior [9] and for its extensive central and peripheral control of energy balance [10]. The eCBs 2-arachidonoylglycerol (2-AG) and anandamide (AEA) are the endogenous lipid mediators of this system and have similar actions to those of the exogenous plant cannabinoid endogenous lipid mediators of this system and have similar actions to those of the exogenous plant cannabinoid endogenous lipid mediators of this system and have similar actions to those of the exogenous plant cannabinoid endogenous lipid mediators of this system and have similar actions to those of the exogenous plant cannabinoid endogenous lipid mediators of this system and have similar actions to those of the exogenous plant cannabinoid endogenous lipid mediators of this system and have similar actions to those of the exogenous plant cannabinoid endogenous lipid mediators of this system and have similar actions to those of the exogenous plant cannabinoid endogenous lipid mediators of this system and have similar actions to those of the exogenous plant cannabinoid endogenous lipid mediators of this system and have similar actions to those of the exogenous plant cannabinoid.

The literature demonstrates significant relationships between the eCB system, Cloninger’s temperament traits and MVPA, all associated with BMI. However, no study has analyzed these...
factors together to assess the modulating effect of eCB functioning and temperament traits on MVPA and lifestyle PA, and the links to BMI in females. Therefore, the aims of the present study were to: 1) examine differences among distinct BMI groups on lifestyle PA levels and time spent in MVPA, temperament traits and plasma eCB concentrations; and 2) explore the association and interaction between MVPA, temperament, eCBs and BMI. Based on the literature, we hypothesized that: 1) Higher BMI would be associated with greater sedentary behavior, altered plasma eCBs and a specific temperament profile; 2) MVPA levels would be linked to specific temperament traits, in particular Novelty seeking, and altered eCB concentration, in particular augmented plasma AEA levels; 3) Both temperament and eCBs would be implicated in the relationship between MVPA and BMI.

Materials and Methods

Ethics statement

All participants gave written informed consent and the Ethics Committees of all the research institutions involved in the data collection approved the study: Comité Ético de Investigación Clínica del Hospital Universitari de Bellvitge; Comité d’Investigació Clínica del Hospital Universitari de Girona Doctor Josep Trueta; Comité Ético de Investigación Clínica del Consorci Mar Parc de Salut de Barcelona-Parc de Salut Mar; Subcomisión de Investigación Clínica del Hospital Universitario “Virgen de la Victoria”; Comité Ético de Investigación Clínica de la Universidad de Navarra; Comité Ético de Investigación Clínica de Galicia & Universidad de Santiago de Compostela; Comissió Deontològica de la Universitat Jaume 1. The study was conducted in accordance with the Declaration of Helsinki.

Participants

The sample comprised 189 female individuals, distributed along the BMI continuum, and included: 30 obese participants (BMI = 30–39.9 kg/m²), 43 morbid obese (BMI ≥ 40 kg/m²), and 116 healthy-weight controls (BMI = 18.5–29.9 kg/m²). Participants were Spanish speakers, with a mean age of 34 years (SD = 12.3) (distribution of mean age by group was: control 27.6–SD = 12.9– and morbid obese 43.5 –SD = 10.2–). Seven centers, all involved in the CIBERObn Spanish Research Network, participated: the Eating Disorders Unit (Department of Psychiatry, University Hospital of Bellvitge-IDIBELL, Barcelona), the Department of Endocrinology at the University Hospital of Santiago (Santiago de Compostela); the Department of Diabetes, Endocrinology and Nutrition (Clinic University Hospital Virgen de Victoria, Malaga); the Department of Endocrinology and Nutrition (University of Navarra, Pamplona); the Diabetes, Endocrinology and Nutrition Department, Biomedical Research Institute of Girona (IdIBGi-Doctor Josep Trueta Hospital, Girona); the Hospital del Mar Medical Research Institute (IMIM, Barcelona) and the Department of Basic Psychology, Clinic and Psychobiology (University Jaume I, Castellón). The obese participants were patients who had been consecutively referred to the clinics mentioned above. Recruitment of the controls took place by means of word-of-mouth and advertisements at the local universities. All controls were from the same catchment area as the obese patients.

Exclusion criteria were: a) having suffered a lifetime history of Axis I mental disorders since many are linked to altered PA and eCB levels and temperament styles, especially depression and eating disorders, which are highly co-morbid with obesity [35,37]; b) having a history of chronic medical illness or a neurological condition (e.g. Parkinson’s disease) that may affect motor capacity; c) use psychoactive medication or drugs that influence PA (e.g. cocaine, beta blockers or thyroid medication) or plasma endocannabinoid concentrations (e.g. cannabis); d) being under 18, as adolescence is characterized by psychobiological changes, or over 60 given that age-related medical conditions (e.g. arthritis) affect physical functioning in daily life. Substance abuse/dependence (including cannabis) and eating disorder diagnoses were conducted face-to-face using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) [38]. The evaluation of general health or mental illnesses was based on the General Health Questionnaire-28 (GHQ-28) [39]. Enrolment into the study was between January 2010 and March 2013.

Measures

Temperament and Character Inventory-Revised (TCI-R) [40]. This questionnaire is composed of 240-items scored on a 5-point Likert scale and measures personality derived from three character and four temperament dimensions. The dimensions reflecting temperament (Harm Avoidance, Novelty seeking, Reward Dependence and Persistence) were assessed, which entailed the analysis of 133 items of the total items in the questionnaire. Evaluation of the Spanish revised version [41] generated an internal consistency (coefficient alpha) of 0.87.

Physical Activity was evaluated with Actiwatch AW7 (Actiwatch AW7; CamNtech Ltd, Cambridge Neurotechnology, Cambridge, UK), a small (39×32×9 mm), light-weight (10.5 g) accelerometer that measures activity. The Actiwatch is worn on the non-dominant wrist for 6 days (4 week days and 1 weekend), from 00:00 hr on day 1 to 00:00 hr on day 7. PA data was calculated in the form of activity counts in a 1-minute epoch length over 24 hours. The counts represent the peak intensity of the movement detected by the Actiwatch AW7. Only the data between 7:00 hr and 23:00 hr was analyzed; a data reduction procedure that has been recommended and conducted in previous studies [42,43]. No detected movement for 10 or more consecutive epochs (10 minutes) was considered as missing (seen as implausible counts or as periods in which the participant was sleeping). In addition, a minimum of 4 days of wear was used as criterion to accept the case. This is the lower recommended minimum to accurately estimate daily PA in adults [42]. Upon analysis of the data, there were no cases of 4 or less days of wear. The Actiwatch 7 software (CamNtech Ltd) was used to extract the data. Two PA variables were assessed:

Daytime PA Daily. PA was calculated in the form of mean counts per minute (counts·min⁻¹) over the 6 days.

Time in SLPA and MVPA. The average amount of time during the day spent in sedentary-light PA (SLPA) and MVPA was calculated using an algorithm proposed by Heil [44]. Employing the activity monitor Actical (Mini Mitter Co., Inc., Bend, OR), another Actiwatch produced by the same manufacturer, which was placed on the ankle, hip and wrist, Heil [44] developed algorithms to predict activity energy expenditure (AEE) in children and adults. To obtain the cut point for MVPA, the formula: 

\[ AEE = 0.02013 + (1.282E-5) \times HAC \]  

was used. This yielded a cut point of 848 counts·min⁻¹. This value predicts a PA intensity of 3 MET, which corresponds to a brisk walk. The algorithm to predict AEE in children has been used in a previous study to identify MVPA from the wrist-worn Actiwatch AW4 (CamNtech Ltd, Cambridge Neurotechnology, Cambridge, UK), an earlier version of the Actiwatch AW7 [45].

The Actiwatch AW4 has reliability as a measure of PA similar to other accelerometers [46]. Wrist worn accelerometers have been used to measure PA in various studies [45,47]. They have also
been found to predict a similar amount of variance in energy expenditure to the hip-placed accelerometers [48,49].

**Body Composition** was assessed using the Tanita Multi-Frequency Body Composition Analyzer MC-180MA (Tanita Corporation, Tokyo, Japan). The Tanita is a weighting instrument utilizing bioelectrical impedance analysis for the screening of body fat and composition. This instrument is repeatedly revised in relation to the reference standards dual-energy X-ray absorptiometry (DEXA) (http://www.bl-biologica.es/tanita_thb.htm) and has been validated against other weighing methods [50]. Height was calculated using a stadiometer.

**Endocannabinoids quantification method.** Blood samples were collected from participants between 8 and 9 am after at least 12 hours of fasting. The blood was centrifuged at 3500 rpm at 4°C for 15–20 min. Plasma aliquots were stored at −30°C until analysis. Plasma concentrations of the eCBs AEA (ng/mL) and 2-AG (ng/mL) were assessed. In addition, the following acylethanolamides OEA (ng/mL) and PEA (ng/mL) were assessed.

The eCB quantification was done with modifications of a previously described methodology of eCB analysis in brain tissue [51]. After adding the following amounts of deuterated analogues (Cayman Chemical, USA) 0.25 ng AEA-d₄, 1 ng PEA-d₄ and OEA-d₄, 5 ng 2-AG to a 0.5 mL aliquot of plasma, eCBs were extracted with a liquid–liquid extraction in tert-butyl-methyl-ether (Merck, Germany) and the extracts analyzed in a LC/MS-MS system (Agilent 6410, USA). ECBs were separated in a C8 column (2.1 x 100 mm x 1.8 μm particle size, Zorbax, Agilent) by gradient chromatography of a mobile phase of water and acetonitrile containing 0.1% formic acid (Merck, Germany). The source operated on the positive electrospray ionization mode and the detection was done by the multiple reactions monitoring mechanism (MRM). The following precursor to product ion transitions were used: m/z 379→287 for 2-AG, m/z 348→62 for AEA, m/z 326→62 for OEA, m/z 300→62 for PEA, m/z 384→287 for 2-AG-d₅, 352→66 for AEA-d₄, m/z 330→66 for OEA-d₄ and m/z 304→66 for PEA-d₄. ECB quantification was done by isotopic dilution of the deuterated analogues response. Variations in precision and accuracy were <15% for the individual sample replicates.

**Procedure**

Experienced psychologists and psychiatrists (all extensively trained in the use of the instruments) completed the clinical and physical assessment in two structured face-to-face interviews. In addition to the first clinical interview, temperament and general health status information was obtained through self-report questionnaires. Prior to assessment, basic anthropometrical features were determined by the TANITA and blood samples were obtained after overnight fasting. The accelerometers provided in the first interview were collected after 7 days in a second face-to-face assessment session.

**Statistical Analysis**

Statistical analysis was carried out with STATA13 for Windows. Analysis of variance (ANOVA) was used to compare BMI, PA level and eCBs between diagnostic subtypes (controls, obese and morbid obese). Polynomial contrasts into ANOVA were explored for the pairwise comparison between morbid obese versus controls (f = −19.2, p = .005) were found. No statistical association emerged between groups of weight and daytime PA levels. Linear trends appeared for TCI-R temperament scales: Novelty seeking (increasing trend), Harm avoidance (increasing trend) and Persistence scales (increasing trend), and an additional quadratic trend for Reward dependence. Statistical differences were found between obese and controls for Novelty seeking (p = .015), Harm avoidance (p < .001) and Reward dependence (p = .002), and between morbid obese and controls for Novelty seeking (p = .038) and Harm avoidance (p < .001). As shown in Table 2, the eCB 2-AG was associated with the distinct BMI groups: positive linear and quadratic trends were obtained for this biological measure and statistical differences emerged in the post-hoc comparison between both obese and morbid obese versus controls.

**Mediation model of Moderate-Vigorous Physical Activity level when including temperament and biological parameters**

Figure 1 shows the path-diagram and standardized structural coefficients for the mediational model between temperament traits, eCBs, MVPA level and BMI. Results were adjusted by the covariate participants’ age. Variables selected for the model accomplished Baron-Kenny’s requirements for mediational paths. No reciprocal association between eCBs and BMI were retained since no statistical effect of eCBs on BMI emerged, and retaining these parameters affected the fitting. Both low Novelty seeking and high Harm avoidance scores were predictive of lower MVPA levels. The eCBs measures AEA and OEA mediated the association between MVPA levels and BMI: a) high MVPA levels were associated with high AEA measures, and elevated AEA values were related to high BMI, b) high MVPA levels were also related to high OEA levels, and low levels for this cannabimimetic were associated with higher BMI. MVP levels and Harm avoidance scores also showed direct effects with BMI (high BMI was predicted by high Harm avoidance and low MVP levels). Pathway of Figure 1 achieved goodness-of-fit: $χ² = 8.36 (p > .30)$, RMSEA = .036, CFI = .99, TLI = .96 and SRMR = .033. Considering each equation level, MVP level achieved low effect size values ($mc = .26$ and $mc² = .07$), while BMI obtained higher ones ($mc = .69$ and $mc² = .48$). The overall $R²$ (coefficient of determination) was very good ($R² = 0.47$).
Table 1. BMI, PA, temperament, endocannabinoids and endocannabinoids related compounds among study groups.

|                                | Controls (n=116) | Obese (n=30)  | Morbid-obese (n=43) | ANOVA: p-value, trends and contrasts | MO vs CO | MO vs OB |
|--------------------------------|-----------------|---------------|---------------------|--------------------------------------|----------|---------|
|                                | Mean  SD        | Mean  SD      | Mean  SD            | Group LT QT OB vs CO                  |          |         |
| Body mass index                | 21.6  2.8       | 35.5  2.3     | 46.2  4.8           | <.001 <.001 .019 13.9* 5.42 24.6* 6.24 10.7* 2.81 |          |         |
| MVPA                           | 67.20  35.18    | 65.84  51.03  | 48.02  33.03        | .016 .008 .283 -1.35 0.03 -19.18* 0.56 -17.82* 0.41 |          |         |
| Daytime PA                     | 297.97  68.77   | 305.31  93.16 | 273.71  72.02       | .120 .109 .196 7.34 0.09 -24.26 0.34 -31.60 0.38 |          |         |
| TCI-R: Novelty-seeking         | 100.3  12.9     | 92.9  18.1    | 94.8  14.1          | .017 .038 .120 -7.35* 0.47 -5.51* 0.41 1.84 0.11 |          |         |
| TCI-R: Harm avoidance          | 92.2  16.1      | 106.7  18.7   | 113.0  19.3         | <.001 <.001 261 14.5* 0.83 20.8* 1.17 6.29 0.33 |          |         |
| TCI-R: Reward depend.          | 99.6  14.4      | 109.0  14.6   | 103.0  13.9         | .008 .194 .010 9.38* 0.65 3.40 0.24 -5.98 0.42 |          |         |
| TCI-R: Persistence             | 111.4  16.8     | 112.8  20.0   | 104.9  19.6         | .100 .050 .210 1.44 0.08 -6.51 0.36 -7.95 0.40 |          |         |
| 2-AG (ng/mL)                   | 1.60  1.02      | 3.34  1.65    | 3.82  2.55          | <.001 <.001 .070 1.74* 1.27 2.22* 1.14 0.48 0.23 |          |         |
| AEA (ng/mL)                    | 0.55  0.17      | 0.59  0.26    | 0.62  0.20          | .160 .069 .874 0.04 0.19 0.07 0.39 0.03 0.13 |          |         |
| PEA (ng/mL)                    | 2.48  0.61      | 2.62  0.94    | 2.41  0.50          | .503 .603 .254 0.13 0.17 -0.07 0.12 -0.20 0.27 |          |         |
| OEA (ng/mL)                    | 4.07  1.39      | 4.13  1.58    | 3.86  0.89          | .672 .425 .567 0.06 0.04 -0.22 0.19 -0.28 0.22 |          |         |

ϕ: Adjusted mean difference in ANOVA. LT: linear trend. QT: quadratic trend. | d |: Cohen's-d. *Bold: significant contrast (p≤0.05 level). Italics: moderate to good effect-size (| d | ≤0.5).

BMI: Body mass index; MVPA: moderate-vigorous physical activity; PA: physical activity; 2-AG: 2-arachidonoylglycerol; AEA: anandamide; OEA: N-oleylethanolamide; PEA: N-palmitoylethanolamine.

doi:10.1371/journal.pone.0104534.t001
The aims of the present study were to analyze the differences between extreme BMI groups on daytime PA, MVPA, temperament and eCBs, and explore whether temperament traits and eCB concentrations are mediators of MVPA in females.

Physical Activity and BMI

As expected, comparison among weight categories showed that the morbid obese participants displayed the least MVPA compared to the healthy-weight participants. Differently, daytime PA did not vary between groups. These findings are in line with the existing literature. A recent study assessing the effects of adherence to MVPA guidelines on BMI and waist circumference detected an inverse association between meeting the PA guidelines and baseline BMI and waist circumference. However, later linear regressions demonstrated that only vigorous PA was significantly correlated with lower BMI [55]. In addition, the authors observed that only high adherence to the MVPA guidelines resulted in decreases in BMI and waist circumference, while stable PA had no effect. Similarly, in another study, a significant trend across weight categories in PA among females was only observed for the time spent in vigorous PA [1]. A hypothesis may be that it is a gradual decrease in time spent in MVPA, rather than daytime activity per se that increases the risk and maintains the global prevalence of obesity. As the present study was a cross-sectional, causality cannot be determined, but our findings suggest that the relationship is more complex.

Temperament and BMI

Regarding temperament, both obese groups (obese and morbid obese), presented a distinct temperament profile from the controls, characterized by greater scores in Harm avoidance and Reward dependence, but lower Novelty seeking. Whereas those studies that included obese participants with comorbid eating disorders (namely Binge Eating Disorder) found higher impulsivity scores [36], those who excluded this group of obese patients reported lower impulsivity levels [30]. This may explain the reason why the high Novelty seeking in obese individuals described in the literature [28] was not found in the present study, as individuals with a history of eating disorders were excluded from it. Similar to previous studies [30], the obese individuals in our study presented a temperament profile characterized by passivity, sensitivity, nervousness, insecurity, and social dependence.

Endocannabinoid concentrations and BMI

One remarkable finding in our study was the elevated level of plasma 2-AG concentrations found in the obese groups, which is keeping with the literature [15]. Di Marzo et al [56] observed that a lifestyle modification program for obese patients resulted in a fall of both 2-AG and AEA concentrations, however only 2-AG was associated with a decrease in visceral adipose tissue, triacylglycerol concentrations, and HDL3-cholesterol concentrations, which suggests that these eCBs may have distinct metabolic roles. The present study therefore provides further support to the increasing evidence for the involvement of eCBs in fat metabolism development. Additional research must be conducted to determine the role of the eCB system in obesity.
Temperament traits and endocannabinoid factors as mediators of Moderate-Vigorous Physical Activity and BMI

As expected, objectively measured MVPA was found to be inversely associated with BMI. Noteworthy, the majority of studies assessing the relationship between BMI and PA have employed subjective measures to assess the latter, namely self-reported questionnaires and surveys. Self-reported PA has been found to differ from more direct assessments, which questions the reliability of self-report measures [57]. The use of an accelerometer in a large sample in the present study therefore overcomes this methodological limitation.

In relation to the association between MVPA and temperament traits, an interesting link was found between MVPA and Novelty seeking and Harm avoidance scores. This is in line with other studies, whereby aspects of Novelty seeking, namely energetic attitude and exploratory behavior, have been found to be related to both motoric activity in animals [34] and weekly hours spent exercising in humans [58]. Whereas individuals with high scores in extraversion (corresponding to high Novelty seeking) have a more sociable and interactive lifestyle, and are thus more likely to be active [27], those with low levels of Novelty seeking tend to be passive, inhibited, and less dynamic, and are therefore expected to adopt a more sedentary lifestyle [26]. In contrast, the Harm avoidance temperament trait is associated with the inhibition of behaviors due to greater pessimistic worry or avoidance [59] and sensitivity to pain expectancy [60]. Individuals scoring higher in this trait are likely to be averse to engaging in MVPA, especially high contact and risky sports, as they avoid any activity in which they may be vulnerable to injury.

Consistent with prior animal [6] and human [20] studies, our results showed that AEA and OEA plasma concentrations but not 2-AG were positively associated with MVPA. Authors have proposed that this may be due to differences in the biosynthesis and degradation mechanisms [61]. Whereas AEA and OEA are N-acyl ethanolamides (NAEs) synthesized from the hydrolysis of N-arachidonoyl phosphatidylethanolamine (NAPE) and degraded by the FAAH, 2-AG is synthesized from other precursors (diacylglycerols) and enzymes (diacylglycerol lipases-a and b) and is primarily degraded by monoacylglycerol lipase (MAGL) [16]. Therefore, given that these eCBs have distinct metabolic pathways, a different interaction with MVPA has been proposed [6].

One discrepancy between our results and those of Heyman et al [57], is that we did not find an association between MVPA and PEA despite that PEA shares the same biosynthetic and degradation pathways of AEA and OEA. This could be because the eCB levels in this study were measured at the basal state, while Heyman et al [61] measured eCB levels after intense exercise. In support to our data, regarding the specific relationships between some NAEs and PA, Gasperi et al [62] found increased activity of FAAH in the lymphocytes of physically active subjects at resting condition. It must be noted that blood eCB levels represent the spillover from many sources and it is not possible to differentiate the tissue of origin. For instance, Caraceni et al [63] found that blood AEA, PEA and OEA levels were correlated with liver function, but eCB levels may vary differently in different tissues such as in the intestine or brain [12,56], or in different depots of the same tissue such as in subcutaneous or visceral fat [14]. The skeletal muscle itself is altered in obesity, with increased expression of CB1 receptors and elevated levels of 2-AG without there being changes in AEA. It has been suggested that, in contrast to 2-AG,
AEA and possibly OEA may have beneficial effects on glucose uptake and mitochondrial biogenesis in the muscle through the activation of other receptors such as peroxisome proliferators (PPARs) or the transient receptor potential vanilloid receptor 1 (TPRV1). In this regard, it has been proposed that PA could be a complementary approach for the treatment of obesity without the side effects of CB1 antagonists [19]. In addition to the PA peripheral effects, the potentiation of the eCB system after MVPA also has positive effects on cognitive functions, again linked to AEA peripheral effects, the potentiation of the eCB system after MVPA [8], which could facilitate the implementation of both preventive and treatment programs for obesity.

Furthermore, in the current study the eCBs AEA and eCB-related compound OEA seem to act as contrasting mediators in the relationship between MVPA and BMI. The underlying mechanism between MVPA and the eCB system activation is not yet clear. It could be due to the increases in stress and glucocorticoid hormones (particularly cortisol) that occur with structured PA and seem to be implicated in the activation of eCB signaling [64]. Separately, eCBs have been found to be implicated in the regulation of appetite (as is the case of marijuana) via the activation of the reward system [65]. When energy homeostasis is challenged, such as in situations of food deprivation, an increase in endocannabinoid levels takes place [66]. The process is associated with a reinforced pleasure obtained from ingestion and from the rewarding properties of food [11,67], which may lead to hyperphagia, overconsumption and consequentially weight gain [68]. Differently, the eCB-related compound OEA is a putative, peripheral satiety factor and anorexinergic mediator, which promotes satiety and reduces weight gain by stimulating the vagal sensory nerves that in turn stimulate the brainstem and hypothalamus [13]. These findings are reflected in the mediation effect of AEA and OEA on the relationship between MVPA and BMI obtained in the current study. MVPA has an inverse direct effect on BMI, which can be attributed to energy expenditure, and a similar indirect relationship may also exist mediated by OEA. Yet, MVPA may also be associated with augmented BMI through the orexigen effect of AEA.

Finally, Novelty seeking and plasma AEA concentrations were both found to be positively linked to MVPA. Van Laere et al [31] evaluated CB1 receptor availability in temperament, finding greater global cerebral CB1 receptor availability to be inversely related to Novelty seeking. Novelty seeking may interact with the eCB system via the engagement in MVPA. Furthermore, the activation of this system with exercise appears to result in exercise-induced analgesia and may be responsible for the reported runner’s high, a transient and intense feeling of happiness, elation, induced analgesia and may be responsible for the reported runner’s high, a transient and intense feeling of happiness, elation, and energy [29]. Our results support the concept that individuals who are high in impulsive traits may engage in PA to achieve a gratifying state, following a positive reinforcement conditioning, whereas more passive and less energetic individuals, such as those who present elevated Harm avoidance, present more sedentary behavior. Reduction in the BMI might be a consequent effect, but also may act as a maintaining factor of this vicious circle. Further research is needed to understand the mechanisms of these associations. For instance OEA is not a CB1 agonist and it is best known for acting as a fat sensor in the intestine, but in a recent report it has been suggested that OEA is also involved in the reward system by stimulating central dopamine activity [69] and may participate in the control of reward-related behaviors through a PPAR2 receptor-independent mechanism [70].

Limitations
The study has a number of limitations that should be considered. First, the study focused of females. Future studies should also assess male participants who are likely to present distinct PA patterns. Second, the accelerometer was placed in the non-dominant wrist. Though this instrument permits a more accurate assessment of PA compared to subjective measures, PA entailing only lower-body movement may not be adequately captured. Future studies should place accelerometers to both the wrist and waist, as well as use self-reported questionnaires in order to obtain a more complete description of the activity patterns of participants. It must also be noted that in the current study plasma eCBs levels were assessed in the morning after an overnight fast, while MVPA was evaluated throughout the day. Although a link between time spent in MVPA and circulating eCBs was observed, a more controlled design should be developed in order to demonstrate the exact cause-effect mechanism. Finally, the cross-sectional nature of the study does not permit causality to be determined. Longitudinal studies should be conducted to evaluate how temperament in adolescence or young adulthood may predict the interaction between eCBs, temperament, and MVPA later in life, and to assess how lifestyle changes with increases in the time spent engaging in MVPA may be related to alterations in the eCB system and BMI.

Despite its limitations, this study has several important strengths, including the substantial sample size. Furthermore, path-analysis is used in this study as a case of structural equation modeling (SEM) with exploratory aims, with the advantage (compared to classical regression models) of allowing the inclusion of multiple relationships among a set of variables, including mediational associations. The results obtained constitute empirical evidence for the development of further theories about the role of MVPA, endocannabinoids and temperament on BMI.

In conclusion, the present study provides further understanding of the pathophysiological mechanism involved in PA and obesity by integrating previously described links between the eCB system, temperament, MVPA, and BMI, to generate a psychobiological model of the relationship between engagement in MVPA and BMI. It was shown that decreases in time spent in MVPA, rather than overall daytime PA, may be underlying the augmentation in obesity, and this may occur through the interaction with both psychological and biological factors. Important clinical conclusions may be drawn to confront the excess obesity among females. Future therapeutic approaches aiming at preventing obesity by reducing sedentary behavior and encouraging exercise, should consider both physiological and behavioral maintaining factors (e.g. attitude and motivation, behavioral tasks, environmental factors, locus of control), and temperament traits. It may be hypothesized that additional psychological interventions focusing on improving enthusiastic and inquiring attitudes, positive own reactions in front of novelty and new goals, might have a positive secondary influence on patients’ attitude towards MVPA.

Author Contributions
Conceived and designed the experiments: FFA SS AP RdlT SJM RB CB JMF. GF FJT ABF ZA FFC. Performed the experiments: FFA SS AP JCFG JGA RR ABF ZA. Analyzed the data: RG. Contributed reagents/materials/analysis tools: FFA SS AP RdlT RB CB JMF. GF JGA FJT FFC. Wrote the paper: FFA SS AP MLG RdlT SJM RR CB JMF. GF JGA FJT JA ABF ZA JM FFC.
References

1. Tudor-Locke C, Brashard MM, Johnson WD, Katzmarzyk PT (2010) Accelerometer profiles of physical activity and inactivity in normal weight, overweight, and obese U.S. men and women. Int J Behav Nutr Phys Act 7: 60.

2. Kelly T, Yang W, Chen GS, Reynolds R, He J (2006) Global burden of obesity in 2005 and projections to 2030. Int J Obes 32(9): 1431–1437.

3. Andrade AM, Coutinho SR, Silva MN, Mata J, Vieira PN, et al. (2010) The effect of physical activity on weight loss is mediated by eating self-regulation. Patient Educ Couns 79(3): 320–326.

4. Bauman A, Bull F, Chey T, Craig CL, Ainsworth BE, et al. (2009) The international physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 41(5): 965–975.

5. Lakerveld J, Dunstan D, Bo S, Salmon J, Dekker J, et al. (2011) Abdominal obesity, TV-viewing time and prospective decline in physical activity. Prev Med 53(4-5): 299–302.

6. Heyman E, Gamelin FX, Aucouturier J, Di Marzo V (2012) The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity. Obes Rev 13(12): 1110–1124.

7. Feuerecker M, Hauer D, Toth R, Demetz F, Holzl J, et al. (2012) Effects of exercise stress on the endocannabinoid system in humans under field conditions. Eur J Appl Physiol 112(7-8): 2777–2781.

8. Ferreira-Vieira TH, Bastos CP, Pereira GS, Moreira FA, Massensini AR (2014) A role for the endocannabinoid system in exercise-induced spatial memory enhancement in mice. Hippocampus 24(1): 79–88.

9. Zamani C, Punini L V, Aliki M, Goldberg SR, Haller J, et al. (2011) Effects of endocannabinoid system modulation on cognition and emotional behavior. Front Behav Neurosci 5: 57.

10. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F (2002) The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 95(4): 375–382.

11. Carrard I, Van der Linden M, Goday A (2012) Comparison of obese and nonobese individuals with dieting disorder: disinhibition and purging in Binge Eating Disorder and Non-Purging Bulimia Nervosa. European Eat Disord Rev 20(3): 350–354.

12. Dr F, Wu L, Luppino F, van Straten A, Penninx B, Zitman F, et al. (2010) Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res 178(2): 230–235.

13. Villarejo C, Fernandez-Arandas F, Jimenez-Murcia S, Pesas-Lledo E, Granero R, et al. (2012) Lifetime obesity in binge eating disorders: increasing prevalence, clinical and personality correlates. Eur Eat Disord Rev 20(3): 250–254.

14. Carrard I, Van der Linden M, Goday A (2012) Comparison of obese and nonobese individuals with dieting disorder: disinhibition and purging in Binge Eating Disorder and Non-Purging Bulimia Nervosa. European Eat Disord Rev 20(3): 350–354.

15. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for Axis I disorders. Clinical version (SCID-CV). Washington: American Psychiatric Press.

16. Goldberg DP (1981) Manual of the general health questionnaire (GHQ-28). Toronto: NFER Nelson Publishing.

17. Cloninger CR (1999) The Temperament and Character Inventory—Revised. St Louis, MO: Center for Psychobiology of Personality, Washington University.

18. Gutierrez-Zotes Bayon C, Montserrat C, Valero J, Labad A, Cloninger RC, et al. (2004) Inventario del Temperamento y el Carácter-Revivido (TC-R). Barambones y datos normativos en una muestra de población general. Actas Españolas Psiquiatr 32 (1): 8–15.

19. Corder K, Brage S, Ekelund U (2007) Accelerometers and pedometers: methodology and clinical application. Curr Opin Clin Nutr Metab Care 10(5): 597–603.

20. Mäše LG, Fuemmeler BF, Anderson CB, Matthews CE, Trost SG, et al. (2005) Accelerometer data reduction: a comparison of four reduction algorithms on select outcome variables. Med Sci Sports Exerc 37(11 Suppl): S54–S55.

21. Heil DP (2006) Predicting activity energy expenditure using the Actical activity monitor. Res Q Exerc Sport 77(3): 248–254.

22. Poronen A-K, Sjöösten NM, Matthews KA, Heinonen K, Martikainen S, et al. (2009) Endocannabinoids and their relation to physical activity, and symptoms of anxiety and depression: the HUNT study. Soc Psychiatry Psychiatr Epidemiol 48(5): 745–756.

23. Ayabe M, Kumahara H, Morimura K, Sakane N, Ishii K, et al. (2013) Temporal associations between daytime physical activity and sleep in children. PLoS One 8(6): e65769.

24. Rounten AC, Upston D, Edwards MG, Peters DM (2012) Intra- and inter-machine reliability of the activPAL 4 accelerometer in a mechanical laboratory setting. J Hum Kinet 31: 17–24.

25. Van der Pas SC, Verbunt JA, Bruekeelar DE, van Woerden R, Seelen HA. Assessment of arm activity using triaxial accelerometry in patients with a stroke. Arch Phys Med Rehabil 92(9): 1437–1442.

26. Ayabe M, Kumahara H, Morimura K, Sakane N, Ishii K, et al. (2013) Accumulation of short bouts of non-exercise daily physical activity is associated with lower visceral fat in Japanese female adults. Int J Sport Med 34(1): 62–67.

27. Kumahara H, Tanaka H, Schutz Y (2004) Daily physical activity assessment: what is the importance of upper limb movements or body movements? Int J Obes Relat Metab Disord 28(9): 1105–1110.

28. Strain GW, Wang J, Gisler M, Pomp A, Inabnet WB, et al. (2008) Biompedance for severe obesity: comparing research methods for total body water and resting energy expenditure. Obesity 16(8): 1953–1956.

29. Busquen-Garcia A, Puigmaner E, Pastor A, de la Torre R, Maldonado R, et al. (2011) Differential role of anandamide and 2-arachidonoylglycerol in the locomotor activity and cognitive index in mice. Exp Neurol 224(1): 106–113.

30. Trappmann D, Blank M, Wipf G, Koelbl-Hofer J, Schiffler M, et al. (2013) Ventral tegmental area cannabinoid type-1 receptors control voluntary exercise performance. Biol Psychiatry 73(9): 895–903.

31. Van Laere K, Goffin K, Borsboom G, Casteels C, Mertens L, et al. (2009) Relationship of type 1 cannabinoid receptor availability in the human brain to novelty-seeking temperament. Arch Gen Psychiatry 66(2): 196–204.

32. Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, et al. (2008) The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 327(2): 539–543.

33. Llarena A, Edman G, Cobaleda J, Benitez J, Schalling D, et al. (1993) Relationship between personality and debrisoquine hydroxylation capacity. Involvement of an endogenous unreactive substrate or product of the cytochrome P450 2D6. Arch Toxicol 67(8): 449–500.

34. Navarrete F, Perez-Oritz JM, Manzanares J (2012) Cannabinoid CB1 receptor-mediated regulation of impulsive-like behaviour in DBA/2 mice. Br J Pharmacol 163(1): 260–273.

35. Kline RB (2010) Principles and practice of structural equation modeling. New York: The Guilford Press.
56. Di Marzo V, Cote M, Matias I, Lemieux I,Arsenault BJ, et al. (2009) Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52(2): 213–217.

57. Prince SA, Adams KB, Hamed ME, Harth J, Connor Gorber S, et al. (2008) A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. Int J Behav Nutr Phys Act 5: 56.

58. Kjelsas E, Augestad LB. Gender, eating behavior, and personality characteristics in physically active students. Scand J Med Sci Sport 14(4): 258–260.

59. Cloninger CR (1994) Temperament and personality. Curr Opin Neurobiol 4(2): 266–273.

60. Ziv M, Toker R, Defrin R, Hendler T (2010) Individual sensitivity to pain expectancy is related to differential activation of the hippocampus and amygdala. Hum Brain Mapp 31(2): 326–338.

61. Heyman E, Gamelin FX, Goekint M, Piscitelli F, Roelands B, et al. (2012) Intense exercise increases circulating endocannabinoid and BDNF levels in humans: possible implications for reward and depression. Psychoneuroendocrinology 37(6): 844–851.

62. Gasperi V, Ceci R, Tantimonaco M, Talamonti E, Battista N, et al. (2014) The fatty acid amide hydrolase in lymphocytes from sedentary and active subjects. Med Sci Sports Exerc 46(1): 24–32.

63. Caraceni P, Viola A, Pucitelli F, Giannone F, Benzigotti A, et al. (2010) Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int 30(6): 816–823.

64. Hill MN, McEwen BS (2010) Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog neuro-psychopharmacology Biol Psychiatry 34(5): 791–797.

65. Kirkham TC, Williams CM (2001) Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 153(2): 267–270.

66. Kirkham TC, Williams CM, Fezza F, Di Marzo V (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136(4): 550–557.

67. Arnone M, Manzini J, Chaperon F, Thiebo M-H, Poncelet M, et al. (1997) Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132(1): 104–106.

68. Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychoneuropharmacology 143(3): 315–317.

69. Tellez LA, Medina S, Han W, Ferreira JG, Licousa-Limón P, et al. (2013) A gut lipid messenger links excess dietary fat to dopamine deficiency. Science 341(6147): 800–802.

70. Bilbao A, Blanco E, Luque-Rojas MJ, Suárez J, Palomino A, et al. (2013) Oleoylthanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARα receptor-independent mechanism 18(1): 78–87.